Toward more accurate preclinical glioblastoma modeling: Reverse translation of clinical standard of care in a glioblastoma mouse model

• Published in: Methods in cell biology Vol. 183; pp. 381 - 397
• Main Authors: Ziani-Zeryouh, Aaron, Wouters, Roxanne, Thirion, Gitte, Vandenbrande, Katja, Vankerckhoven, Ann, Berckmans, Yani, Bevers, Sien, Verbeeck, Jelle, De Keersmaecker, Kim, Coosemans, An, Riva, Matteo
• Format: Journal Article
• Language: English
• Published: United States 2024
• Subjects: Animals; Brain Neoplasms - drug therapy; Glioblastoma - drug therapy; Humans; Mice; Standard of Care; Temozolomide - therapeutic use; Surgery; Combination therapies; Glioblastoma; HGG; Mouse model; Preclinical; Temozolomide; CT-2A; Radiotherapy
• ISSN: 0091-679X
• DOI: 10.1016/bs.mcb.2023.07.003

Glioblastoma (GBM) is the deadliest of all brain cancers. GBM patients receive an intensive treatment schedule consisting of surgery, radiotherapy and chemotherapy, which only modestly extends patient survival. Therefore, preclinical studies are testing novel experimental treatments. In such preclinical studies, these treatments are administered as monotherapy in the majority of cases; conversely, in patients the new treatments are always combined with the standard of care. Most likely, this difference contributes to the failure of clinical trials despite the successes of the preclinical studies. In this methodological study, we show in detail how to implement the full clinical standard of care in preclinical GBM research. Systematically testing new treatments, including cellular immunotherapies, in combination with the clinical standard of care can result in a better translation of preclinical results to the clinic and ultimately increase patient survival.